Consensus EPS · Q2 2026
$2.15
Consensus revenue · Q2 2026
$1.3B
Analysts
9
Expected report
Jul 30, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 9 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.4B |
| EPS | $1.63 | $2.15 | $3.49 |
| EBITDA | -$476.1M | -$455.4M | -$431.2M |
| EBIT | -$522.6M | -$499.9M | -$473.4M |
| Net income | $176.5M | $222M | $279.4M |
- Revenue$1.3B
- EPS$2.15
- EBITDA-$455.4M
- EBIT-$499.9M
- Net income$222M
Historical beat/miss
Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.
| Period | Rev. actual | Rev. est. | Rev. surprise | EPS actual | EPS est. | EPS surprise |
|---|---|---|---|---|---|---|
| Q1 2026 | $1.2B | $1.1B | +4.6% | $1.51 | $0.87 | +73.3% |
- Q1 2026+4.6%+73.3%
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Alnylam Pharmaceuticals (ALNY) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 5 analysts.
- Low
- $400.00
- Consensus
- $438.50
- Median
- $436.50
- High
- $485.00
- Current
- $266.99
- Upside
- +64.2%
Upside calculated vs most recent trading price of $266.99.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 52 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 14, 2026 | B of A Securities | maintain | Buy | Buy |
| Jul 13, 2026 | Truist Securities | maintain | Buy | Buy |
| Jul 13, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 10, 2026 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Jun 29, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 4, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 5, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 1, 2026 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| May 1, 2026 | RBC Capital | maintain | Outperform | Outperform |
| Apr 13, 2026 | Truist Securities | maintain | Buy | Buy |
- Jul 14, 2026B of A SecuritiesBuy
- Jul 13, 2026Truist SecuritiesBuy
- Jul 13, 2026HC Wainwright & Co.Buy
- Jul 10, 2026Morgan StanleyEqual Weight
- Jun 29, 2026HC Wainwright & Co.Buy
- Jun 4, 2026HC Wainwright & Co.Buy
- May 5, 2026HC Wainwright & Co.Buy
- May 1, 2026Wells FargoEqual Weight
- May 1, 2026RBC CapitalOutperform
- Apr 13, 2026Truist SecuritiesBuy
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.